Skip to main content
OpenTrials
Completed

NCT Number: NCT00421408

The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women

Women and men consuming a low protein diet may be at risk for bone loss. The purpose of this study is to determine whether a daily protein supplement will improve bone health among healthy older adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bone Resorption Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases Osteoporosis

Age range

60 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University of Connecticut Health Center, Farmington, Connecticut, United States

Loading trial locations.

About this study

Dietary protein plays an important role in maintaining balanced calcium levels in the body. Protein's impact on skeletal health remains unclear. It is well accepted that increasing dietary protein results in greater excretion of calcium through urine. The excreted calcium is thought to come in part from bone, which would suggest a negative effect on bone health. However, recent studies have found that higher protein intake is, in fact, associated with higher bone mineral density and lower rates of bone loss. The purpose of this study is to determine if a daily protein supplement will improve bone health and hormonal measures of bone metabolism among healthy older men and women who consume low-to-normal levels of dietary protein.

This study will last 18 months. For the duration of the study, participants will be randomly assigned to receive either a 40-gram protein supplement or placebo daily. There will be a total of nine study visits that will occur at screening, study entry, Month 1.5, and every three months thereafter. Dietary records, nutritional counseling, glucose finger stick tests, and questionnaires related to falls, physical activity, habits, and study satisfaction will occur at all study visits. Blood and urine collection, functional testing, and bone mineral density (BMD) testing will occur at selected visits. At Months 0 and 18, half of the participants will undergo a quantitative computed tomography (CT) scan to determine bone mineral density.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to travel to one of the study sites
  • Women age 60 years or greater, men age 70 years or greater
  • Dietary protein intake level between 0.6 g/kg and 1.0 g/kg at baseline

Exclusion criteria

  • Active Paget's disease
  • Primary hyperparathyroidism or unexplained hypercalcemia
  • Untreated hyperthyroidism or hyperthyroidism that has resulted from medical treatment
  • Diabetes mellitus type 1
  • Cancer diagnosis for solid malignancies (e.g., cancer of the colon, breast,prostate, lungs, lymphocytes) within the 18 months prior to study entry
  • Long-term use of chemotherapeutic drugs, aromatase inhibitors, or tamoxifen
  • Active treatment for leukemia or multiple myeloma
  • Active inflammatory bowel disease
  • Life expectancy of less than 2 years
  • Current and ongoing use of methotrexate, phenytoin, phenobarbital, or inhaled corticosteroids at a dose of greater than 800 mcg/day
  • Use of raloxifene, estrogen, androgen, progesterone, soy isoflavones, oral glucocorticoids, or herbal supplements with estrogenic activity OR a change in dosage of thyroid medications within the 1 year prior to study entry if unwilling to avoid such agents during the duration of the study
  • Current use of antiresorptive agents (e.g., calcitonin or bisphosphonates). More information about this criterion can be found in the protocol.
  • serum creatinine greater than 1.2 mg/dl
  • History of chronic liver disease or evidence of liver disease at screening
  • Bilateral hip replacement
  • women who have a bone mineral density T-score < -2.5 at either the hip or spine unless they have decided to decline treatment with conventional anti-osteoporotic medications
  • Body mass index (BMI) greater than 32 or less than 19
  • Use of proton-pump inhibitors taken twice daily
  • Fasting glucose level greater than 110 mg/dl
  • Serum albumin level less than 3.0 mg/dl
  • Kidney stones or history of kidney stones within the 3 years prior to study entry

Treatment and study plan

Whey Protein Supplement

Dietary Supplement

40-g whey protein supplement daily for 18 months

Placebo

Dietary Supplement

Placebo supplement daily for 18 months

Primary outcomes

  1. Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline

    Time frame: Measured at baseline and 18 months

    There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.

  2. Change in Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) Compared to Baseline

    Time frame: Measured at baseline and 18 months

    There is no normative data for quantitative computed tomography it is based on local experience.

  3. Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at Baseline

    Time frame: Measured at 0 months

    There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.

  4. Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 9 Months

    Time frame: Measured at 9 months

    There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.

  5. Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 18 Months

    Time frame: Measured at 18 months

    There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.

  6. Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at Baseline

    Time frame: Measured at 0 months

    There is no normative data for quantitative computed tomography it is based on local experience.

  7. Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at 18 Months

    Time frame: Measured at 18 months

    There is no normative data for quantitative computed tomography it is based on local experience.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • Office of Dietary Supplements (ODS)

Registry information

Official study title

Impact of a Protein Supplement on Bone Mass in Older Men and Women

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
Jan 12, 2007
Registry last updated
Apr 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.